PEG-G-CSF
Phase 3Small molecule
SanofiPEG-G-CSF is one of 31 small molecule programs targeting Neutropenia. It is currently in Phase 3.
1
Indications
5
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Neutropenia
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Maxipime
PfizerApproved
Merrem
BB. Braun Medical Inc.
Approved
Levaquin
WWim Janssens
Approved
Amikin
IInsmed Incorporated
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Neutropenia3 trials
Prostate Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PEG-G-CSF. EMBL-EBI & Wellcome Sanger Institute.
- [4]